Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
1
25%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Active, not recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)

Trials by Status

active_not_recruiting250%
recruiting250%

Recent Activity

4 active trials
Showing 4 of 4
active_not_recruitingphase_1

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

NCT02473536
active_not_recruitingphase_2

Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

NCT02141919
recruitingphase_2

Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care

NCT06556550
recruitingnot_applicable

Metastases Directed Therapy for Oligometastatic Breast Cancer

NCT06144346

Clinical Trials (4)

Showing 4 of 4 trials
NCT02473536Phase 1

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

Active Not Recruiting
NCT02141919Phase 2

Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer

Active Not Recruiting
NCT06556550Phase 2

Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care

Recruiting
NCT06144346Not Applicable

Metastases Directed Therapy for Oligometastatic Breast Cancer

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4